Zepbound 2.5 mg/.5mL

Tirzepatide, the active ingredient in Zepbound, is a dual GIP/GLP-1 receptor agonist presented as a 2.5 mg/0.5 mL injection solution for subcutaneous use. It is indicated for chronic weight management in adults with obesity or overweight who have at least one weight-related comorbidity, as an adjunct to diet and exercise.

GNH USA supplies Zepbound as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zepbound contains tirzepatide and acts on incretin pathways involved in metabolic regulation.

- Chronic weight management: Used in adults with obesity, or overweight with at least one weight-related comorbidity, as an adjunct to diet and exercise. - Obesity treatment support: Helps support weight reduction in eligible adults when prescribed and monitored as part of a broader care plan. - Overweight with comorbidity: Used in adults with overweight status who also have a weight-related condition that warrants treatment. - Long-term weight management: Intended for ongoing management of excess body weight when a clinician determines it is appropriate.

Zepbound can cause adverse effects that vary in frequency and severity.

Common Side Effects: - Nausea: Frequently reported, especially during treatment initiation or dose changes. - Diarrhea: May occur and can contribute to fluid loss. - Vomiting: Can happen in some patients and may worsen dehydration risk. - Constipation: A commonly reported gastrointestinal effect. - Abdominal pain: Stomach or abdominal discomfort may occur. - Decreased appetite: May accompany treatment and contribute to reduced food intake. Serious or Rare Side Effects: - Pancreatitis: Severe, persistent abdominal pain with or without vomiting requires prompt evaluation. - Gallbladder problems: Gallstones or inflammation of the gallbladder have been reported. - Hypoglycemia: Risk increases when used with insulin or insulin secretagogues. - Kidney injury from dehydration: Can occur if vomiting or diarrhea leads to volume depletion.

Zepbound should be used with standard clinical precautions and product-label guidance.

- Assess suitability: Confirm the indication and review the full medication history before prescribing or dispensing. - Monitor gastrointestinal tolerance: Nausea, vomiting, diarrhea, and constipation may be clinically significant. - Watch for pancreatitis symptoms: Persistent severe abdominal pain should be evaluated promptly. - Review diabetes medicines: Hypoglycemia risk may increase when used with insulin or sulfonylureas. - Use in pregnancy and breastfeeding: Safety data are limited; clinical decisions should be made by a qualified prescriber. - Store at 2-8°C: Keep refrigerated, protect from light, and do not freeze or shake.

Tirzepatide may interact with other medicines and can require closer monitoring.

Major Interactions (Avoid): - Concomitant insulin use: Can raise the risk of clinically important hypoglycemia. - Sulfonylureas: May also increase hypoglycemia risk when combined. - Other GLP-1-based therapies: Overlapping pharmacology may increase tolerability concerns without established benefit. Moderate Interactions (Monitor Closely): - Oral medicines needing reliable absorption: Slowed gastric emptying may affect absorption timing. - Antidiabetic agents: Blood glucose should be monitored when therapy is adjusted. - Drugs sensitive to dehydration: Vomiting or diarrhea may increase adverse-effect risk through fluid loss.